InnoPharm-2025 to Spotlight Breakthroughs in Drug Discovery, Delivery & Novel Modalities
Global pharma leaders, scientists, and innovators will gather in San Francisco from Nov 03–05, 2025, to explore transformative sessions.
Themed around Drug Discovery, Development, Delivery Systems, and Novel Modalities, InnoPharm-2025 will feature keynote talks, panel discussions, and interactive sessions addressing the most pressing challenges and opportunities in modern drug innovation.
Topics will include:
AI and Machine Learning in Therapeutics
Next-generation biologics and small molecules
Peptide and RNA-based therapeutics
Drug-device combination strategies
Molecular glues and targeted protein degradation
Advanced delivery platforms for precision medicine
Regulatory landscapes and translational challenges
The conference offers a unique networking platform where academia meets industry, providing opportunities for collaborations, partnerships, and investment discussions that could accelerate the path from discovery to patient benefit.
“InnoPharm-2025 is more than just a scientific conference — it’s a forum to shape the future of healthcare innovation,” said Gayatri Srinivas, Conference Manager. “With experts from around the world, participants can expect to gain actionable insights into emerging therapies and breakthrough technologies.”
Delegates will include pharmaceutical researchers, biotech entrepreneurs, venture capitalists, healthcare providers, and regulatory leaders, making this event a hub for cross-disciplinary learning and partnerships.
Early registration is now open, and attendees are encouraged to secure their participation to take advantage of discounted rates.
For details, visit: https://pharm-science.com/
Gayatri Srinivas
CO-IN Symposia
+1 512-270-2990
contact@pharmaresearchers.com
Visit us on social media:
LinkedIn
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
